Sweden’s Karo Pharma is poised to strengthen its OTC portfolio by acquiring a basket of brands mainly sold in the Nordics from Israeli generics giant Teva for €84m ($102m). The transaction is slated to close on 1 April 2021.
Six consumer health brands are included the deal, which generated combined sales of just under €35m in 2020. The vast...







